KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Receivables - Other: 2013-2024

Historic Receivables - Other for Acadia Pharmaceuticals (ACAD) over the last 12 years, with Dec 2024 value amounting to $6.0 million.

  • Acadia Pharmaceuticals' Receivables - Other rose 94.08% to $23.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.6 million, marking a year-over-year increase of 94.08%. This contributed to the annual value of $6.0 million for FY2024, which is 45.87% up from last year.
  • Acadia Pharmaceuticals' Receivables - Other amounted to $6.0 million in FY2024, which was up 45.87% from $4.1 million recorded in FY2023.
  • In the past 5 years, Acadia Pharmaceuticals' Receivables - Other registered a high of $6.0 million during FY2024, and its lowest value of $885,000 during FY2022.
  • Moreover, its 3-year median value for Receivables - Other was $4.1 million (2023), whereas its average is $3.6 million.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Receivables - Other plummeted by 51.94% in 2021 and then spiked by 361.36% in 2023.
  • Over the past 5 years, Acadia Pharmaceuticals' Receivables - Other (Yearly) stood at $2.0 million in 2020, then tumbled by 51.94% to $978,000 in 2021, then fell by 9.51% to $885,000 in 2022, then skyrocketed by 361.36% to $4.1 million in 2023, then surged by 45.87% to $6.0 million in 2024.